

Supplementary Table S3. Medication use in all women with SLE, and grouped according to inactive and active disease in 2nd trimester.

n/N* (%)	Total SLE population	Inactive disease (LAI—P = 0)	Active disease (LAI-P > 0)	P-value
1st trimester	134	69	53	
hydroxychloroquine	99 (73.9)	54 (80.6)	35 (68.6)	0.20
azathioprine	38 (28.4)	21 (31.4)	16 (31.4)	1.0
prednisolone	58 (43.6)	26 (38.8)	26 (51.0)	0.26
acetylsalicylic acid	59 (43.7)	26 (40.0)	23 (46.0)	0.52
2nd trimester	168	85	63	
hydroxychloroquine	115 (68.5)	59 (70.2)	45 (72.6)	0.90
azathioprine	47 (28.0)	21 (25.0)	23 (37.1)	0.16
prednisolone	72 (42.9)	32 (38.1)	36 (58.1)	0.03
acetylsalicylic acid	94 (57.0)	46 (56.1)	39 (65.0)	0.37
3rd trimester	160	88	59	
hydroxychloroquine	117 (73.1)	66 (75.9)	41 (71.9)	0.74
azathioprine	47 (29.4)	25 (28.4)	20 (35.1)	0.50
prednisolone	71 (44.4)	33 (37.5)	33 (57.9)	0.03
acetylsalicylic acid	86 (53.8)	46 (52.9)	31 (59.6)	0.55

N* may differ from N due to missing data